Hauptseite > Publikationsdatenbank > Detection of Amyloid-ß aggregates in body fluids: A suitable method for early diagnosis of Alzheimer's disease? > print

001     4525
005     20200402205610.0
024 7 _ |2 WOS
|a WOS:000266522800011
037 _ _ |a PreJuSER-4525
041 _ _ |a eng
082 _ _ |a 610
084 _ _ |2 WoS
|a Clinical Neurology
084 _ _ |2 WoS
|a Neurosciences
100 1 _ |a Funke, S. A.
|b 0
|u FZJ
|0 P:(DE-Juel1)VDB65869
245 _ _ |a Detection of Amyloid-ß aggregates in body fluids: A suitable method for early diagnosis of Alzheimer's disease?
260 _ _ |a Hilversum
|b Bentham Science Publishers Ltd.
|c 2009
300 _ _ |a 285 - 289
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
440 _ 0 |a Current Alzheimer Research
|x 1567-2050
|0 20682
|y 3
|v 6
500 _ _ |a Record converted from VDB: 12.11.2012
520 _ _ |a Today, the most reliable diagnosis for Alzheimer's disease (AD) is the post mortem identification of amyloid plaques, consisting of the Amyloid-beta (A beta) peptide, (and neurofibrillary tangles) in the brain of the patient. Great efforts are being made to identify reliable biomarkers for AD that are suitable for minimal invasive early diagnosis and prognosis of AD. During the past years, body fluids of AD patients were assayed for their content of total or soluble A beta (1-40) or A beta (1-42) concentrations using classical (ELISA) or non-classical (with additional signal amplification) read-out. Cerebrospinal fluid (CSF) concentrations of soluble A beta (1-42) are reduced by 40 to 50 % in AD patients compared to age-matched healthy controls as confirmed in more than 30 studies, with both sensitivity and specificity exceeding 80 % in most of the studies. Thus, it was suggested that low levels of CSF A beta (1-42) might be useful for preclinical diagnosis. Because the current average sensitivity of AD biomarker detection in the CSF is approximately 85 %, these assays do not offer a considerable increase in predictive value over existing algorithms based on neuropsychological and imaging modalities. Regarding the amyloid cascade hypothesis, A beta oligomers and aggregates are directly involved in the pathogenic process. Therefore, presence of A beta aggregates seem to be the most direct disease biomarker for AD and increasing effort is being made into the development of methods suitable for the detection of different A beta aggregates in body fluids like CSF and plasma. We therefore give an overview of the current state of A beta aggregate specific detection.
536 _ _ |a Funktion und Dysfunktion des Nervensystems
|c P33
|2 G:(DE-HGF)
|0 G:(DE-Juel1)FUEK409
|x 0
588 _ _ |a Dataset connected to Web of Science
650 _ 7 |a J
|2 WoSType
653 2 0 |2 Author
|a Alzheimer's disease
653 2 0 |2 Author
|a early-diagnosis
653 2 0 |2 Author
|a prognosis
653 2 0 |2 Author
|a therapy monitoring
653 2 0 |2 Author
|a Amyloid-beta aggregates
653 2 0 |2 Author
|a protein misfolding diseases
653 2 0 |2 Author
|a biomarker
700 1 _ |a Birkmann, E.
|b 1
|u FZJ
|0 P:(DE-Juel1)VDB65870
700 1 _ |a Willbold, D.
|b 2
|u FZJ
|0 P:(DE-Juel1)132029
773 _ _ |g Vol. 6, p. 285 - 289
|p 285 - 289
|q 6<285 - 289
|0 PERI:(DE-600)2155964-8
|t Current Alzheimer research
|v 6
|y 2009
|x 1567-2050
909 C O |o oai:juser.fz-juelich.de:4525
|p VDB
913 1 _ |k P33
|v Funktion und Dysfunktion des Nervensystems
|l Funktion und Dysfunktion des Nervensystems
|b Gesundheit
|0 G:(DE-Juel1)FUEK409
|x 0
914 1 _ |y 2009
915 _ _ |0 StatID:(DE-HGF)0010
|a JCR/ISI refereed
920 1 _ |k ISB-3
|l Strukturbiochemie
|d 31.12.2010
|g ISB
|0 I:(DE-Juel1)VDB942
|x 0
970 _ _ |a VDB:(DE-Juel1)111557
980 _ _ |a VDB
980 _ _ |a ConvertedRecord
980 _ _ |a journal
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)IBI-7-20200312
981 _ _ |a I:(DE-Juel1)ICS-6-20110106

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21